Episurf Medical AB (STO:EPISB), a provider of minimally invasive and personalised treatment alternatives for people with painful joint injuries, announced on Friday that it has CE-marked a new knee joint visualisation tool, which will be released to the European market following a controlled launch process.
This tool, named Epioscopy, is a web-based application based on artificial intelligence (AI), providing an overview of a knee joint's clinical condition.
According to the company, Epioscopy is intended to assist healthcare professionals in their planning of optimal treatments for patients' knees by interactive 3D visualisation of structures and possible structural deviations.
Episurf Medical offers the Episealer personalised implants and Epiguide surgical drill guides, which are developed for treating localised cartilage injury in joints. Episurf Medical's µiFidelity system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention.
GelMEDIX completes USD13m seed financing, announces first partnership
AmacaThera named Life Sciences Ontario Emerging Company of the Year
GenSight Biologics reports first patient treated in GS010 REVISE study
Biophytis secures Asian partnership and investment to advance Phase 3 sarcopenia programme
MemorialCare hospitals recognised in 2026 Women's Choice Awards
Champions Oncology expands bioanalytical services with new technology and leadership
PhaseV receives three industry honours for AI in clinical development
Galapagos plans to wind down cell therapy business following strategic review
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025
Revelation Pharma acquires Acacia Apothecary & Wellness
Viatris receives fifth consecutive recognition on Forbes' annual list of World's Best Employers